Page 17 - இந்‌ஸ்டிடூடோ டி மருத்துவ மூலக்கூறு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Shorter Infusion Time for MS Therapy Ocrevus

FDA Approves Shorter Infusion Time for MS Therapy Ocrevus 4.5 (49) The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion time to a two-hour session from the previously approved 3.5 hours. This may ease Ocrevus’ administration burden for patients and have a positive impact on healthcare resources. “More than 170,000 people with MS have been treated with Ocrevus the only approved B-cell therapy with a twice-yearly dosing schedule and it is the most prescribed MS medicine in the U.S.,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in a press release. A subsidiary of Roche, Genentech is the developer of Ocrevus.

Marta figueiredoLevi garrawayUniversity of lisbonLeiden university medical centerEuropean unionDrug administrationBiomedical sciencesDevelopmental biologyMedical microbiologyInfectious diseasesApplied biologyInstituto de medicina molecularமார்த்தா பிகுேய்ரேதோலெவி க்யாரவபல்கலைக்கழகம் ஆஃப் லிஸ்பன்ஐரோப்பிய தொழிற்சங்கம்

Study Seeks to Better Understand How MS Affects Memory

Study Seeks to Better Understand How MS Affects Memory 4.5 (19) A new research project will seek to better understand the biological processes that drive memory problems in people with multiple sclerosis (MS), as a better understanding of these processes may open new avenues for intervention. The four-year study is titled “Neuroimaging of Hippocampally Mediated Memory Dysfunction in Multiple Sclerosis,” and received funding totaling $651,997 from the National Multiple Sclerosis Society. Its principal investigator is Joshua Sandry, PhD, assistant professor of psychology at Montclair State University. Also collaborating on the study is Ekaterina Dobryakova, PhD, a research scientist in the Center for Traumatic Brain Injury Research at Kessler Foundation. She will oversee the clinical project, including advanced neuroimaging studies conducted at the Rocco Ortenzio Center for Neuroimaging at Kessler Foundation.

United statesJoshua sandryEkaterina dobryakovaNeuroimaging at kessler foundationNational multiple sclerosis societyRocco ortenzio centerTraumatic brain injury research at kessler foundationMontclair state universityLeiden university medical centerSociety of americaUniversity of pittsburghHippocampally mediated memory dysfunctionMultiple sclerosisNational multiple sclerosisMontclair stateTraumatic brain injury research

Ublituximab Superior to Aubagio at Lowering MS Relapse Rates, Data Show

Ublituximab Superior to Aubagio at Lowering MS Relapse Rates, Data Show
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Lawrence steinmanMarta figueiredoSanofi genzyme aubagioMichaels weissUniversity of lisbonLeiden university medical centerStanford universityBiomedical sciencesDrug designationSanofi genzymeDevelopmental biologyMedical microbiologyInfectious diseasesApplied biologyInstituto de medicina molecularலாரன்ஸ் ஸ்டெய்ன்மேன்

Inflammatory Environment in MS Found to Impair Myelin Debris-clearing

Inflammatory Environment in MS Found to Impair Myelin Debris-clearing
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Marta figueiredoUniversity of lisbonLeiden university medical centerInternational journal of molecular sciencesBiomedical sciencesMultiple sclerosisInternational journalDevelopmental biologyMedical microbiologyInfectious diseasesApplied biologyInstituto de medicina molecularமார்த்தா பிகுேய்ரேதோபல்கலைக்கழகம் ஆஃப் லிஸ்பன்சர்வதேச இதழ் ஆஃப் மூலக்கூறு அறிவியல்உயிர் மருத்துவ அறிவியல்

Nasal Delivery of Interferon-beta Shows MS Treatment Potential in Mice

Nasal Delivery of Interferon-beta Shows MS Treatment Potential in Mice
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

University of torontoUniversity of chileMerck kgaLeiden university medical centerMerck kgaaDrug administrationMedical microbiologyInfectious diseasesApplied biologyInstituto de medicina molecularபல்கலைக்கழகம் ஆஃப் டொராண்டோபல்கலைக்கழகம் ஆஃப் சிலிமெர்க் க்கமருத்துவ நுண்ணுயிரியல்தொற்று நோய்கள்பயன்படுத்தப்பட்டது உயிரியல்